Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society...
Ausführliche Beschreibung
Autor*in: |
Giacobbe DR [verfasserIn] Ciacco E [verfasserIn] Girmenia C [verfasserIn] Pea F [verfasserIn] Rossolini GM [verfasserIn] Sotgiu G [verfasserIn] Tascini C [verfasserIn] Tumbarello M [verfasserIn] Viale P [verfasserIn] Bassetti M [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Infection and Drug Resistance - Dove Medical Press, 2009, (2020), Seite 4697-4711 |
---|---|
Übergeordnetes Werk: |
year:2020 ; pages:4697-4711 |
Links: |
---|
Katalog-ID: |
DOAJ050697137 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ050697137 | ||
003 | DE-627 | ||
005 | 20230308154442.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)DOAJ050697137 | ||
035 | |a (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RC109-216 | |
100 | 0 | |a Giacobbe DR |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance | ||
650 | 4 | |a cefiderocol | |
650 | 4 | |a siderophore | |
650 | 4 | |a pseudomonas | |
650 | 4 | |a acinetobacter | |
650 | 4 | |a enterobacterales | |
650 | 4 | |a antimicrobial resistance | |
653 | 0 | |a Infectious and parasitic diseases | |
700 | 0 | |a Ciacco E |e verfasserin |4 aut | |
700 | 0 | |a Girmenia C |e verfasserin |4 aut | |
700 | 0 | |a Pea F |e verfasserin |4 aut | |
700 | 0 | |a Rossolini GM |e verfasserin |4 aut | |
700 | 0 | |a Sotgiu G |e verfasserin |4 aut | |
700 | 0 | |a Tascini C |e verfasserin |4 aut | |
700 | 0 | |a Tumbarello M |e verfasserin |4 aut | |
700 | 0 | |a Viale P |e verfasserin |4 aut | |
700 | 0 | |a Bassetti M |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Infection and Drug Resistance |d Dove Medical Press, 2009 |g (2020), Seite 4697-4711 |w (DE-627)600305996 |w (DE-600)2494856-1 |x 11786973 |7 nnns |
773 | 1 | 8 | |g year:2020 |g pages:4697-4711 |
856 | 4 | 0 | |u https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc |z kostenfrei |
856 | 4 | 0 | |u https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1178-6973 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |j 2020 |h 4697-4711 |
author_variant |
g d gd c e ce g c gc p f pf r g rg s g sg t c tc t m tm v p vp b m bm |
---|---|
matchkey_str |
article:11786973:2020----::vlaigeieooiteramnomlirgeitngangtvbcl |
hierarchy_sort_str |
2020 |
callnumber-subject-code |
RC |
publishDate |
2020 |
allfields |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc DE-627 ger DE-627 rakwb eng RC109-216 Giacobbe DR verfasserin aut Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases Ciacco E verfasserin aut Girmenia C verfasserin aut Pea F verfasserin aut Rossolini GM verfasserin aut Sotgiu G verfasserin aut Tascini C verfasserin aut Tumbarello M verfasserin aut Viale P verfasserin aut Bassetti M verfasserin aut In Infection and Drug Resistance Dove Medical Press, 2009 (2020), Seite 4697-4711 (DE-627)600305996 (DE-600)2494856-1 11786973 nnns year:2020 pages:4697-4711 https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc kostenfrei https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR kostenfrei https://doaj.org/toc/1178-6973 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 4697-4711 |
spelling |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc DE-627 ger DE-627 rakwb eng RC109-216 Giacobbe DR verfasserin aut Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases Ciacco E verfasserin aut Girmenia C verfasserin aut Pea F verfasserin aut Rossolini GM verfasserin aut Sotgiu G verfasserin aut Tascini C verfasserin aut Tumbarello M verfasserin aut Viale P verfasserin aut Bassetti M verfasserin aut In Infection and Drug Resistance Dove Medical Press, 2009 (2020), Seite 4697-4711 (DE-627)600305996 (DE-600)2494856-1 11786973 nnns year:2020 pages:4697-4711 https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc kostenfrei https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR kostenfrei https://doaj.org/toc/1178-6973 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 4697-4711 |
allfields_unstemmed |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc DE-627 ger DE-627 rakwb eng RC109-216 Giacobbe DR verfasserin aut Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases Ciacco E verfasserin aut Girmenia C verfasserin aut Pea F verfasserin aut Rossolini GM verfasserin aut Sotgiu G verfasserin aut Tascini C verfasserin aut Tumbarello M verfasserin aut Viale P verfasserin aut Bassetti M verfasserin aut In Infection and Drug Resistance Dove Medical Press, 2009 (2020), Seite 4697-4711 (DE-627)600305996 (DE-600)2494856-1 11786973 nnns year:2020 pages:4697-4711 https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc kostenfrei https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR kostenfrei https://doaj.org/toc/1178-6973 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 4697-4711 |
allfieldsGer |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc DE-627 ger DE-627 rakwb eng RC109-216 Giacobbe DR verfasserin aut Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases Ciacco E verfasserin aut Girmenia C verfasserin aut Pea F verfasserin aut Rossolini GM verfasserin aut Sotgiu G verfasserin aut Tascini C verfasserin aut Tumbarello M verfasserin aut Viale P verfasserin aut Bassetti M verfasserin aut In Infection and Drug Resistance Dove Medical Press, 2009 (2020), Seite 4697-4711 (DE-627)600305996 (DE-600)2494856-1 11786973 nnns year:2020 pages:4697-4711 https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc kostenfrei https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR kostenfrei https://doaj.org/toc/1178-6973 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 4697-4711 |
allfieldsSound |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc DE-627 ger DE-627 rakwb eng RC109-216 Giacobbe DR verfasserin aut Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases Ciacco E verfasserin aut Girmenia C verfasserin aut Pea F verfasserin aut Rossolini GM verfasserin aut Sotgiu G verfasserin aut Tascini C verfasserin aut Tumbarello M verfasserin aut Viale P verfasserin aut Bassetti M verfasserin aut In Infection and Drug Resistance Dove Medical Press, 2009 (2020), Seite 4697-4711 (DE-627)600305996 (DE-600)2494856-1 11786973 nnns year:2020 pages:4697-4711 https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc kostenfrei https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR kostenfrei https://doaj.org/toc/1178-6973 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2020 4697-4711 |
language |
English |
source |
In Infection and Drug Resistance (2020), Seite 4697-4711 year:2020 pages:4697-4711 |
sourceStr |
In Infection and Drug Resistance (2020), Seite 4697-4711 year:2020 pages:4697-4711 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance Infectious and parasitic diseases |
isfreeaccess_bool |
true |
container_title |
Infection and Drug Resistance |
authorswithroles_txt_mv |
Giacobbe DR @@aut@@ Ciacco E @@aut@@ Girmenia C @@aut@@ Pea F @@aut@@ Rossolini GM @@aut@@ Sotgiu G @@aut@@ Tascini C @@aut@@ Tumbarello M @@aut@@ Viale P @@aut@@ Bassetti M @@aut@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
600305996 |
id |
DOAJ050697137 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ050697137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308154442.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ050697137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giacobbe DR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino &ndash; IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L&rsquo;Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant&rsquo;Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Universit&agrave; Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino &ndash; IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-&beta;-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cefiderocol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">siderophore</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pseudomonas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acinetobacter</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enterobacterales</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antimicrobial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ciacco E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Girmenia C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pea F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossolini GM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sotgiu G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tascini C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tumbarello M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viale P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bassetti M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Infection and Drug Resistance</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 4697-4711</subfield><subfield code="w">(DE-627)600305996</subfield><subfield code="w">(DE-600)2494856-1</subfield><subfield code="x">11786973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:4697-4711</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6973</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">4697-4711</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Giacobbe DR |
spellingShingle |
Giacobbe DR misc RC109-216 misc cefiderocol misc siderophore misc pseudomonas misc acinetobacter misc enterobacterales misc antimicrobial resistance misc Infectious and parasitic diseases Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
authorStr |
Giacobbe DR |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)600305996 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC109-216 |
illustrated |
Not Illustrated |
issn |
11786973 |
topic_title |
RC109-216 Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data cefiderocol siderophore pseudomonas acinetobacter enterobacterales antimicrobial resistance |
topic |
misc RC109-216 misc cefiderocol misc siderophore misc pseudomonas misc acinetobacter misc enterobacterales misc antimicrobial resistance misc Infectious and parasitic diseases |
topic_unstemmed |
misc RC109-216 misc cefiderocol misc siderophore misc pseudomonas misc acinetobacter misc enterobacterales misc antimicrobial resistance misc Infectious and parasitic diseases |
topic_browse |
misc RC109-216 misc cefiderocol misc siderophore misc pseudomonas misc acinetobacter misc enterobacterales misc antimicrobial resistance misc Infectious and parasitic diseases |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Infection and Drug Resistance |
hierarchy_parent_id |
600305996 |
hierarchy_top_title |
Infection and Drug Resistance |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)600305996 (DE-600)2494856-1 |
title |
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
ctrlnum |
(DE-627)DOAJ050697137 (DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc |
title_full |
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
author_sort |
Giacobbe DR |
journal |
Infection and Drug Resistance |
journalStr |
Infection and Drug Resistance |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
4697 |
author_browse |
Giacobbe DR Ciacco E Girmenia C Pea F Rossolini GM Sotgiu G Tascini C Tumbarello M Viale P Bassetti M |
class |
RC109-216 |
format_se |
Elektronische Aufsätze |
author-letter |
Giacobbe DR |
author2-role |
verfasserin |
title_sort |
evaluating cefiderocol in the treatment of multidrug-resistant gram-negative bacilli: a review of the emerging data |
callnumber |
RC109-216 |
title_auth |
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
abstract |
Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance |
abstractGer |
Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance |
abstract_unstemmed |
Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L’Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant’Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino – IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-β-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
title_short |
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data |
url |
https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR https://doaj.org/toc/1178-6973 |
remote_bool |
true |
author2 |
Ciacco E Girmenia C Pea F Rossolini GM Sotgiu G Tascini C Tumbarello M Viale P Bassetti M |
author2Str |
Ciacco E Girmenia C Pea F Rossolini GM Sotgiu G Tascini C Tumbarello M Viale P Bassetti M |
ppnlink |
600305996 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
callnumber-a |
RC109-216 |
up_date |
2024-07-03T16:16:13.167Z |
_version_ |
1803575228550348801 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ050697137</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308154442.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ050697137</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf9ccfebb841a427bbc13fffdc31a34cc</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Giacobbe DR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Daniele Roberto Giacobbe,1,2 Eugenio Ciacco,3 Corrado Girmenia,4 Federico Pea,5,6 Gian Maria Rossolini,7,8 Giovanni Sotgiu,9 Carlo Tascini,10 Mario Tumbarello,11,12 Pierluigi Viale,5,6 Matteo Bassetti1,2 On behalf of the ISGRI-SITA (Italian Study Group on Resistant Infections of the Italian Society of Anti-infective Therapy)1Clinica Malattie Infettive, Ospedale Policlinico San Martino &ndash; IRCCS, Genoa, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Pharmacy Unit, S. Salvatore Hospital, ASL1 Abruzzo, L&rsquo;Aquila, Italy; 4Hematology, Dipartimento Medicina Traslazionale e di Precisione, AOU Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; 5Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy; 6University Hospital IRCCS Policlinico Sant&rsquo;Orsola Bologna, Bologna, Italy; 7Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 8Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy; 9Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 10SOC Malattie Infettive, Azienda Sanitaria Integrata, University of Udine, Udine, Italy; 11Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; 12Dipartimento di Sicurezza e Bioetica, Universit&agrave; Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Daniele Roberto GiacobbeClinica Malattie Infettive, Ospedale Policlinico San Martino &ndash; IRCCS, L.go R. Benzi 10, Genoa 16132, ItalyTel +390105554658Email daniele.roberto.giacobbegmail.comAbstract: Infections due to multidrug-resistant Gram-negative bacteria (MDR-GNB), especially when carbapenem resistant, have been very difficult to manage in the last fifteen years, owing to the paucity of dependable therapeutic options. Cefiderocol is a siderophore cephalosporin recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) that may have the potential to fill some of the remaining gaps in the treatment of MDR-GNB infections. Among others, cefiderocol demonstrated in vitro activity against carbapenem-resistant Acinetobacter baumannii and metallo-&beta;-lactamases producers. Clinical data from both registrative studies and post-marketing experiences are essential to confirm whether these promises from in vitro studies could readily translate into clinical practice, as well as to delineate the precise place in therapy for cefiderocol for the treatment of MDR-GNB in the near future. Because of its unique potential, it is essential to provide both randomized controlled trials (RCT) and real-life data to improve the ability of clinicians to exploit its benefit in both empirical and targeted treatment of MDR-GNB infections. In this narrative review, we discuss the emerging data from pivotal RCT and initial real-life experiences on the use of cefiderocol for the treatment of MDR-GNB infections.Keywords: cefiderocol, siderophore, Pseudomonas, Acinetobacter, Enterobacterales, antimicrobial resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cefiderocol</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">siderophore</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pseudomonas</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">acinetobacter</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">enterobacterales</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antimicrobial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ciacco E</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Girmenia C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pea F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rossolini GM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sotgiu G</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tascini C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tumbarello M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viale P</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Bassetti M</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Infection and Drug Resistance</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2020), Seite 4697-4711</subfield><subfield code="w">(DE-627)600305996</subfield><subfield code="w">(DE-600)2494856-1</subfield><subfield code="x">11786973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2020</subfield><subfield code="g">pages:4697-4711</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f9ccfebb841a427bbc13fffdc31a34cc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/evaluating-cefiderocol-in-the-treatment-of-multidrug-resistant-gram-ne-peer-reviewed-article-IDR</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6973</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2020</subfield><subfield code="h">4697-4711</subfield></datafield></record></collection>
|
score |
7.399642 |